AKT1 and central nervous system cancer: The potential therapeutic mechanism of miR‐29a/b/c in glioma is to inhibit tumor cell proliferation by downregulating cyclin D1 expression, phosphorylation of AKT, GSK‐3β, and thus inducing G1 blockade.